MCRB Profile
Seres Therapeutics Inc. (MCRB) is a microbiome therapeutics company headquartered in Cambridge, Massachusetts, USA. The company is focused on developing microbiome therapies to treat various diseases by modulating the composition of the microbiome.
Seres' lead product candidate is SER-109, an investigational oral microbiome therapeutic designed to prevent recurrent Clostridioides difficile infection (rCDI). SER-109 is currently being evaluated in a Phase 3 clinical trial, and Seres has also submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of SER-109 for the treatment of rCDI. Seres is also developing other product candidates for the treatment of various diseases, including SER-301, a microbiome therapeutic for the treatment of ulcerative colitis.
In September 2021, Seres announced that it had entered into a collaboration agreement with AstraZeneca to develop microbiome therapies for the treatment of various diseases. Under the terms of the agreement, Seres will receive an upfront payment and is eligible to receive additional milestone payments and royalties based on the achievement of certain development, regulatory, and commercial milestones.
As of September 30, 2021, Seres had cash, cash equivalents, and marketable securities of $131.2 million. The company has incurred significant research and development expenses as it continues to advance its pipeline of product candidates.
Seres' stock is listed on the NASDAQ stock exchange and has a market capitalization of approximately $790 million as of February 21, 2023. The stock has experienced significant volatility in recent years and investors should carefully consider the risks associated with investing in a clinical-stage microbiome therapeutics company.
|
